MannKind (MNKD) said Friday it agreed to a $50 million private placement with institutional investors led by Frazier Life Sciences.
The firm is selling about 10.4 million common shares for $3.89 each and pre-funded warrants to buy up to roughly 2.4 million shares at $3.88 per warrant, the company said.
The transaction is expected to close on or about Friday, and the business plans to use the net proceeds for general corporate purposes, including a $45 million contingent value rights payment related to the recent US Food and Drug Administration approval of Furoscix ReadyFlow, MannKind said.
Shares of the company were up 6.4% in Friday premarket trading.